Hofseth Biocare (Norway) Performance
| HBC Stock | NOK 3.04 0.04 1.33% |
Hofseth Biocare holds a performance score of 18 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of -1.05, which attests to a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning Hofseth Biocare are expected to decrease slowly. On the other hand, during market turmoil, Hofseth Biocare is expected to outperform it slightly. Use Hofseth Biocare ASA total risk alpha, value at risk, and the relationship between the standard deviation and treynor ratio , to analyze future returns on Hofseth Biocare ASA.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Hofseth Biocare ASA are ranked lower than 18 (%) of all global equities and portfolios over the last 90 days. Despite quite conflicting fundamental indicators, Hofseth Biocare disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 172.8 M | |
| Total Cashflows From Investing Activities | -37.9 M |
Hofseth |
Hofseth Biocare Relative Risk vs. Return Landscape
If you would invest 130.00 in Hofseth Biocare ASA on November 29, 2024 and sell it today you would earn a total of 174.00 from holding Hofseth Biocare ASA or generate 133.85% return on investment over 90 days. Hofseth Biocare ASA is generating 1.7145% of daily returns assuming 7.4229% volatility of returns over the 90 days investment horizon. Simply put, 66% of all stocks have less volatile historical return distribution than Hofseth Biocare, and 66% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Hofseth Biocare Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Hofseth Biocare's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Hofseth Biocare ASA, and traders can use it to determine the average amount a Hofseth Biocare's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.231
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | HBC | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.42 actual daily | 66 66% of assets are less volatile |
Expected Return
| 1.71 actual daily | 34 66% of assets have higher returns |
Risk-Adjusted Return
| 0.23 actual daily | 18 82% of assets perform better |
Based on monthly moving average Hofseth Biocare is performing at about 18% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Hofseth Biocare by adding it to a well-diversified portfolio.
Hofseth Biocare Fundamentals Growth
Hofseth Stock prices reflect investors' perceptions of the future prospects and financial health of Hofseth Biocare, and Hofseth Biocare fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Hofseth Stock performance.
| Return On Equity | -0.95 | |||
| Return On Asset | -0.19 | |||
| Profit Margin | (1.14) % | |||
| Operating Margin | (1.07) % | |||
| Current Valuation | 1.03 B | |||
| Shares Outstanding | 395.08 M | |||
| Price To Earning | (4.13) X | |||
| Price To Book | 5.19 X | |||
| Price To Sales | 8.29 X | |||
| Revenue | 87.62 M | |||
| EBITDA | (87.72 M) | |||
| Cash And Equivalents | 36.52 M | |||
| Cash Per Share | 0.12 X | |||
| Total Debt | 123.31 M | |||
| Debt To Equity | 188.20 % | |||
| Book Value Per Share | 0.39 X | |||
| Cash Flow From Operations | (61.78 M) | |||
| Earnings Per Share | (0.38) X | |||
| Total Asset | 415.97 M | |||
| Retained Earnings | (105 M) | |||
| Current Asset | 52 M | |||
| Current Liabilities | 74 M | |||
About Hofseth Biocare Performance
By examining Hofseth Biocare's fundamental ratios, stakeholders can obtain critical insights into Hofseth Biocare's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Hofseth Biocare is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Hofseth BioCare ASA, a biotech company, offers value added biomarine ingredients and finished products for human consumption and pet in Norway. The company was founded in 2000 and is headquartered in lesund, Norway. HOFSETH BIOCARE operates under Pharmaceuticals And Biosciences classification in Norway and is traded on Oslo Stock Exchange. It employs 44 people.Things to note about Hofseth Biocare ASA performance evaluation
Checking the ongoing alerts about Hofseth Biocare for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Hofseth Biocare ASA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Hofseth Biocare ASA is way too risky over 90 days horizon | |
| Hofseth Biocare ASA appears to be risky and price may revert if volatility continues | |
| Hofseth Biocare ASA has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| The company reported the revenue of 87.62 M. Net Loss for the year was (126.46 M) with profit before overhead, payroll, taxes, and interest of 28.51 M. | |
| Hofseth Biocare ASA has accumulated about 36.52 M in cash with (61.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.12. | |
| Roughly 53.0% of the company shares are held by company insiders |
- Analyzing Hofseth Biocare's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Hofseth Biocare's stock is overvalued or undervalued compared to its peers.
- Examining Hofseth Biocare's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Hofseth Biocare's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Hofseth Biocare's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Hofseth Biocare's stock. These opinions can provide insight into Hofseth Biocare's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Hofseth Stock
Hofseth Biocare financial ratios help investors to determine whether Hofseth Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hofseth with respect to the benefits of owning Hofseth Biocare security.